IPO - Profile


Our mission is to accelerate genomics for the advancement of science and medicine. The genomic tools and technologies developed over the last two decades since the first sequencing of the human genome have greatly improved our understanding of biology, empowered the development of novel therapies, and advanced clinical diagnostics. And yet the transformative potential of genomics is just starting to be realized.

For example, in oncology, we are just at the beginning of an era in which cancer can be detected early, analyzed at the molecular level, treated with targeted therapies, More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$22.00 10,200,000 Positive High 46.64%

Offering Team

  • Legal counsel
  • Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 24 May, 2021

Offer 27 May, 2021

Look Ahead

Lock Up Expiry Nov 27, 2021

IPO Terms

Offer Price $22.00
Offer Size 10M

Market Sentiments

Stock Price